Neoadjuvant Relatlimab and Nivolumab for Resectable Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Nature 2022 Nov 01;611(7934)155-160, RN Amaria, M Postow, EM Burton, MT Tezlaff, MI Ross, C Torres-Cabala, IC Glitza, F Duan, DR Milton, K Busam, L Simpson, JL McQuade, MK Wong, JE Gershenwald, JE Lee, RP Goepfert, EZ Keung, SB Fisher, A Betof-Warner, AN Shoushtari, M Callahan, D Coit, EK Bartlett, D Bello, P Momtaz, C Nicholas, A Gu, X Zhang, BR Korivi, M Patnana, SP Patel, A Diab, A Lucci, VG Prieto, MA Davies, JP Allison, P Sharma, JA Wargo, C Ariyan, HA TawbiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.